Jairam Krishnamurthy

Huntsman Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Background With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC. Our team developed an app called My MBC Journey to focus on the collection of important information for patients with MBC between clinical encounters. Objective This study will evaluate the usability and satisfaction of My MBC Journey, a mobile app designed for MBC, to inform future modifications. Methods This mixed methods study will assess patient use and satisfaction with the My MBC Journey app to inform future app modifications and identify the barriers and facilitators to the app’s use for enhancing patient-provider communication. We will recruit a prospective, cross-sectional convenience sample of 25 patients with MBC and a sample of 15 members of the care team (ie, caregivers, nurse navigators, and medical oncologists). Applying iterative, convergent mixed methods, we will conduct qualitative, semistructured interviews with the patients and care team members. We also will collect quantitative data on usability through app analytics and standardized questionnaires (ie, the Mobile Application Rating Scale, the Mobile Application Rating Scale user version, and the System Usability Scale). Qualitative interviews will be audio recorded and analyzed using NVivo software to identify mHealth implementation themes. Results The study’s results will inform future app design modifications and gauge preliminary effect size in support of future evaluations of the app’s efficacy in improving patient-provider communication. Conclusions Our long-term goal is to improve patient-provider communication by developing mHealth apps that empower patients to collect and share clinically relevant, patient-reported information in a timely manner. International Registered Report Identifier (IRRID) PRR1-10.2196/66050

Year:

2025

Background/Objectives: Chemotherapy-induced neuropathic pain (CINP) represents a critical challenge in oncology, emerging as a common and debilitating side effect of widely used chemotherapeutic agents, such as paclitaxel (PTX). Current therapeutic interventions and preventive strategies for CINP are largely insufficient, as they fail to address the underlying peripheral nerve damage, highlighting an urgent need for the development of new drugs. This study aimed to investigate the dual-function effects on normal cell protection and tumor suppression of BMX-001, a redox-active manganese metalloporphyrin that has demonstrated antioxidant and anti-inflammatory properties, which offers potential in protecting central nervous system tissues and treating CINP. Methods: This study assessed BMX-001’s different roles in protecting normal cells while acting as a pro-oxidant and pro-inflammatory molecule in cancer cells in vitro. We also evaluated its neuroprotective effect in preclinical PTX-induced CINP models in vivo. Results: Our results showed significant reductions in mechanical and cold allodynia, decreased pro-inflammatory cytokine levels, and restored antioxidant capacity in peripheral nerves and dorsal root ganglia (DRGs) following BMX-001 treatment. Conclusions: Overall, our study highlights the therapeutic potential of BMX-001 to mitigate CINP and enhance anticancer efficiency. Its dual-selective mechanism supports the future clinical investigation of BMX-001 as a novel adjunct to chemotherapeutic regimens.

Year:

2025

Background: About 15–20% of breast cancers are HER2 positive. Approximately 15–24% of individuals with localized HER2-positive cancer develop metastatic disease after curative treatment, while 3–10% present with de novo metastasis. Survival has significantly improved with various anti-HER2 agents, but there is considerable heterogeneity at the individual level. Our study aims to identify factors influencing survival in de novo metastatic HER2-positive breast cancer using a large sample from the National Cancer Database (NCDB). Methods: Women with metastatic HER2-positive breast cancer diagnosed from 2010 to 2020 in the NCDB were included. Demographic, clinicopathological, treatment data, and overall survival (OS) were collected. Kaplan–Meier curves estimated OS. The log-rank test identified OS differences between groups in univariate analysis. The Cox proportional hazard model with backward elimination identified factors affecting OS in multivariate analysis. The 12-month, 36-month, and 60-month survival estimates, 95% confidence intervals (CIs), and adjusted hazard ratios were reported. Results: Among 5376 women with metastatic HER2-positive breast cancer from 2010 to 2020, the median OS was 55.95 months (95% CI 53.55-NE). Multivariate analysis identified age, Charlson–Deyo comorbidity score, histology, HER2 IHC expression, hormone receptor status, the number of metastatic sites, metastasis location, first-line chemotherapy, anti-HER2 therapy, hormone-blocking therapy, surgery at primary/non-primary sites, and palliative treatment as significant factors affecting OS. Race and radiation receipt were not significant. Conclusions: This is the largest analysis of overall survival estimates in de novo metastatic HER2-positive breast cancer to date in the real-world setting. We identified several independent prognostic factors influencing OS in this population. These findings will help individualize prognostication at diagnosis, optimize treatment strategies, and facilitate patient stratification in future trials.

Year:

2025

Year:

2025

Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.

Year:

2025

Year:

2024

BACKGROUND With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC. Our team developed an app called My MBC Journey to focus on the collection of important information for patients with MBC between clinical encounters. OBJECTIVE This study will evaluate the usability and satisfaction of My MBC Journey, a mobile app designed for MBC, to inform future modifications. METHODS This mixed methods study will assess patient use and satisfaction with the My MBC Journey app to inform future app modifications and identify the barriers and facilitators to the app’s use for enhancing patient-provider communication. We will recruit a prospective, cross-sectional convenience sample of 25 patients with MBC and a sample of 15 members of the care team (ie, caregivers, nurse navigators, and medical oncologists). Applying iterative, convergent mixed methods, we will conduct qualitative, semistructured interviews with the patients and care team members. We also will collect quantitative data on usability through app analytics and standardized questionnaires (ie, the Mobile Application Rating Scale, the Mobile Application Rating Scale user version, and the System Usability Scale). Qualitative interviews will be audio recorded and analyzed using NVivo software to identify mHealth implementation themes. RESULTS The study’s results will inform future app design modifications and gauge preliminary effect size in support of future evaluations of the app’s efficacy in improving patient-provider communication. CONCLUSIONS Our long-term goal is to improve patient-provider communication by developing mHealth apps that empower patients to collect and share clinically relevant, patient-reported information in a timely manner. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/66050

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (16)

Andrew A. Davis

Washington University in St. Louis

UNITED STATES
View details

Wei Shi

Assistant Professor

University of Nebraska Medical Center

UNITED STATES
View details

PAVANKUMAR TANDRA

Assistant professor with a special interest in Breast Oncology

University of Nebraska Medical Center

UNITED STATES
View details

Thaís Fávero Alves

Assistant professor

University of Nebraska Medical Center

UNITED STATES
View details

Foluso O. Ademuyiwa

-

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Richard Schilsky

Chief Medical Officer

-

UNITED STATES
View details

Susan Halabi

Duke University

UNITED STATES
View details

Rama Suresh

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Kaitlyn Crosby

Assistant Professor

University of Nebraska Medical Center

UNITED STATES
View details

Bin Duan

Professor

University of Nebraska Medical Center

UNITED STATES
View details

Lindsay L. Peterson

Washington University School of Medicine

UNITED STATES
View details

jingqin luo

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Melanie Cozad

Associate Professor

University of Nebraska Medical Center

UNITED STATES
View details

Rebecca Oberley-Deegan

University of Nebraska Medical Center

UNITED STATES
View details

Hongying Daisy Dai

-

UNITED STATES
View details